As healthcare professionals, we encounter pyrexia, or fever, regularly in clinical practice. Despite its common occurrence, its management can be complex, necessitating a comprehensive understanding of its etiology, pathophysiology, and treatment options.
Pyrexia is a physiological response to various conditions, most commonly infections. It results from the release of pyrogens, which reset the hypothalamic temperature set-point, leading to increased body temperature. Understanding the underlying cause is crucial in managing pyrexia effectively.
Assessment of the febrile patient should include a thorough history and physical examination. Key factors to consider are the duration and pattern of the fever, associated symptoms, and potential exposure to infectious agents. Laboratory investigations, such as complete blood count, inflammatory markers, and cultures, can provide valuable information.
Treatment of pyrexia primarily focuses on addressing the underlying cause. In cases of infection, appropriate antibiotics should be administered. Antipyretics, such as paracetamol and non-steroidal anti-inflammatory drugs, can be used to alleviate discomfort but should not replace the treatment of the underlying cause. In some cases, pyrexia can be a helpful physiological response, enhancing immune function and inhibiting pathogen growth.
Special considerations should be given to immunocompromised patients, as their fevers may indicate serious infections. Elderly patients may present atypically, with confusion or falls instead of fever. In neonates, pyrexia may be the only sign of serious bacterial infection and warrants immediate investigation.
In conclusion, managing pyrexia in clinical practice requires a comprehensive approach, understanding its etiology, conducting a thorough assessment, and implementing appropriate treatment. Special attention should be given to vulnerable populations. As healthcare professionals, our role is not just to treat the fever, but to understand and address its underlying cause.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation